Research output per year
Research output per year
Personal profile
Education/Academic qualification
ADR, Autorisation de Diriger la Recherche, University of Luxembourg
Award Date: 20 Mar 2026
PhD, Cellular and molecular biology , University of Reims Champagne-Ardenne, Faculty of Pharmacy
Award Date: 11 Dec 2004
Master, Biochemistry, molecular and cellular Biology , University of Reims Champagne-Ardenne, Faculty of Exact and Natural Sciences
Award Date: 9 Jul 2001
Bachelor, Biological sciences (biochemistry specialty), University of Reims Champagne-Ardenne (URCA), Faculty of Exact and Natural Sciences
Award Date: 5 Jul 1999
Fingerprint
Dive into the research topics where Michael Schnekenburger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Dual Beclin 1 post-translational reprogramming by BCR-ABL and HDAC6 inhibition disables autophagic flux and overcomes CML resistance
Paik, J. Y., Lee, Y., Li, V., Boyer-Orlikova, B., Kirsch, G., Cerella, C., Schnekenburger, M. & Diederich, M., 10 Oct 2026, In: Cancer Letters. 658, 218755.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia
Paik, J. Y., Gajulapalli, S. R., Li, V., Park, S., Lee, Y., Orlikova-Boyer, B., Lorant, A., Christov, C., Kirsch, G., Kang, H. J., Schnekenburger, M., Cerella, C. & Diederich, M., Aug 2026, In: Biomedicine and Pharmacotherapy. 201, 119652.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics
Florean, C., Lernoux, M., Lorant, A., Losson, H., Bormans, G., Schnekenburger, M. & Diederich, M., 1 Mar 2025, In: Haematologica. 110, 3, p. 784-790 7 p.Research output: Contribution to journal › Letter › peer-review
Open Access1 Citation (Scopus) -
Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Yang, H., Li, V., Park, S. J., Cheon, S. W., Lorant, A., Mazumder, A., Lee, J. Y., Orlikova-Boyer, B., Cerella, C., Christov, C., Kirsch, G., Olberg, D. E., Bormans, G., Kang, H. J., Han, B. W., Schnekenburger, M. & Diederich, M., 16 Jul 2025, In: Clinical Epigenetics. 17, 1, 27 p., 125.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
Preparation and pharmacological characterization of the enantiomers of the anticancer agent R/S-N-3-cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea: Identification of the R-enantiomer as the active eutomer
Schnekenburger, M., Goffin, E., Schoumacher, M., Tumanov, N., Mouithys-Mickalad, A., de Tullio, P., Wouters, J., Lebrun, P., Diederich, M. & Pirotte, B., Apr 2025, In: European Journal of Medicinal Chemistry Reports. 13, 100244.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus)